MTOR and neoplasm: Activation of the PI3K/AKT/mTOR pathway results in phosphorylation of FOXO1 and prevents it from entering the nucleus [150], providing a mechanistic explanation for the enhanced anti-tumor effect of HDAC inhibitor and PI3K/mTOR inhibitor combination therapy [149,151].